To provide preclinical proof-of-concept of the therapeutic actionability of CDK12-induced SGOC metabolic alterations, we generated patient-derived xenografts (PDXs) from CDK12HIGH (Patients #1 and #2) and CDK12LOW (Patients #3 and #4) human breast cancers (Fig. 9a). This evidence concerns the gene CDK12 and breast cancer.